Sandbox Reserved 1237
From Proteopedia
Line 14: | Line 14: | ||
No work has yet been done on specific Slx-2 binding to Gb3, but it can be assumed due to the homology present between the two, as well as their shared receptor, that the mechanisms are roughly the same. The binding of the B subunit to G3b occurs at one to three receptor sites on the subunits, the third of which is has a lower affinity than the first two. As the B subunits bind with high affinity, the cluster of verotoxin expands laterally across the membrane, causing it to invaginate with or without the assistance of cellular tubules such as actin or dynamin. Such invagination give way to the formation of vesicles which transport the toxins into the cell. Once there, the A subunit is cleaved by the action of furin to form A1 and A2. A2 keeps A1 bound to the B pentamer, while A1 carries out the endohydrolysis of the N-glycosidic bond at a specific adenosine on the 28S rRNA unit of a 60S ribosome. This halts protein synthesis, killing the cell. With Stx, the dead cells release cytokines and chemokines, which play a role in platelet activation. Stx also inactivates ADAMTS13, which is involved in cleaving a protein that is involved in blood clotting, thus increasing the level of platelet activation further, eventually leading to the formation of microthrombi. [3],[4],[5],[6]. | No work has yet been done on specific Slx-2 binding to Gb3, but it can be assumed due to the homology present between the two, as well as their shared receptor, that the mechanisms are roughly the same. The binding of the B subunit to G3b occurs at one to three receptor sites on the subunits, the third of which is has a lower affinity than the first two. As the B subunits bind with high affinity, the cluster of verotoxin expands laterally across the membrane, causing it to invaginate with or without the assistance of cellular tubules such as actin or dynamin. Such invagination give way to the formation of vesicles which transport the toxins into the cell. Once there, the A subunit is cleaved by the action of furin to form A1 and A2. A2 keeps A1 bound to the B pentamer, while A1 carries out the endohydrolysis of the N-glycosidic bond at a specific adenosine on the 28S rRNA unit of a 60S ribosome. This halts protein synthesis, killing the cell. With Stx, the dead cells release cytokines and chemokines, which play a role in platelet activation. Stx also inactivates ADAMTS13, which is involved in cleaving a protein that is involved in blood clotting, thus increasing the level of platelet activation further, eventually leading to the formation of microthrombi. [3],[4],[5],[6]. | ||
+ | |||
+ | [[Image:http://www.nature.com/nrmicro/journal/v8/n2/images/nrmicro2279-f1.jpg]] | ||
+ | Three sites of B subunit bound to G3b, and two A subunits | ||
== Disease == | == Disease == |
Revision as of 00:02, 5 May 2017
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
Verotoxin-2
|
References
1. Fraser ME, et al. "Structure of Shiga Toxin Type 2 (Stx2) from Escherichia Coli O157:H7." J.Biol.Chem. 279(26). (2004). 27511-7
2. http://www.rcsb.org/pdb/explore/explore.do?structureId=1R4P
3. Römer W, et al. "Shiga toxin induces tubular membrane invaginations for its uptake into cells." Nature. (2007). 450(7170):670-675
4. Ray PE, Lui XH. "Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome." Pediatr Nephrol. 2001. 16(10):823-39
5. O'Loughlin EV, Robins-Brown RM. "Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells." Microbes Infect. (2001). 3(6):492-507
6. Melton-Celsa AR. “Shiga Toxin (Stx) Classification, Structure, and Function.” Microbiology spectrum. (2014). 2(2):PMC
7. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. "Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals." Toxins. (2012). 4(11):1261-1287
8. McGannon1 CM, Fuller CA, Weiss AA. "Different Classes of Antibiotics Differentially Influence Shiga Toxin Production." Antimicrob. Agents Chemother. (2010). 54(9):3790-3798
9. Bielaszewska M, et al. "Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain" Antimicrob. Agents Chemother. (2012). 56(6):3277-3282
10. Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. "Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype." Frontiers in Cellular and Infection Microbiology. (2015). 5(24):PMC
11. Law, D. "The history and evolution of Escherichia coli O157 and other Shiga toxin-producing E. coli". World Journal of Microbiology and Biotechnology. (2000). 16(8):701-709.
12. Martínez-Castillo A, Muniesa M. "Implications of free Shiga toxin-converting bacteriophages occurring outside bacteria for the evolution and the detection of Shiga toxin-producing Escherichia coli." Frontiers in Cellular and Infection Microbiology. (2014). 4(46):PMC
13. O'Brien AD, Holmes RK. "Shiga and Shiga-like toxins." Microbiological Reviews. (1987). 51(2):206-220